Read by QxMD icon Read

Clinical Genitourinary Cancer

Emina Kayama, Eiji Kikuchi, Keishiro Fukumoto, Suguru Shirotake, Yasumasa Miyazaki, Kyohei Hakozaki, Gou Kaneko, Shunsuke Yoshimine, Nobuyuki Tanaka, Maeda Takahiro, Kunimitsu Kanai, Masafumi Oyama, Yosuke Nakajima, Satoshi Hara, Tetsuo Monma, Mototsugu Oya
PURPOSE: To investigate whether a history of non-muscle-invasive bladder cancer (NMIBC) plays a prognostic role in patients with muscle-invasive bladder cancer (MIBC) treated with radical cystectomy in the era when neoadjuvant chemotherapy was established as standard therapy for MIBC. PATIENTS AND METHODS: A total of 282 patients who were diagnosed with cT2-T4aN0M0 bladder cancer treated with open radical cystectomy at our institutions were included. Initially diagnosed MIBC without a history of NMIBC was defined as primary MIBC group (n = 231), and MIBC that progressed from NMIBC was defined as progressive MIBC (n = 51)...
April 28, 2018: Clinical Genitourinary Cancer
Thenappan Chandrasekar, Neil Pugashetti, Zachary Klaassen, Hanan Goldberg, Paul Dong, Stanley A Yap
No abstract text is available yet for this article.
April 28, 2018: Clinical Genitourinary Cancer
Xin Gao, Opeyemi Jegede, Connor Gray, Paul J Catalano, Jesse Novak, David J Kwiatkowski, Rana R McKay, Daniel J George, Toni K Choueiri, David F McDermott, Sabina Signoretti, Rupal S Bhatt
INTRODUCTION: Genomic events leading to activation of mechanistic target of rapamycin (mTOR) are common in renal cell carcinoma (RCC). Everolimus is an allosteric mTOR inhibitor with efficacy in metastatic RCC. We characterized the genomic profile of RCC tumors from metastatic sites and assessed whether particular alterations correlate with clinical response to everolimus. PATIENTS AND METHODS: An open-label, single-arm phase 2 biomarker study of everolimus 10 mg daily was conducted in metastatic RCC patients...
April 25, 2018: Clinical Genitourinary Cancer
Gesa Isensee, Anne Péporté, Joachim Müller, Sabine Schmid, Silke Gillessen, Aurelius Omlin
INTRODUCTION: Radium-223 is an approved survival-prolonging treatment option in men with castration-resistant prostate cancer (mCRPC) and bone metastases. In the registration trial (ALSYMPCA), no regular imaging was mandated. We aimed to analyze men with metastatic mCRPC treated with radium-223 who had bone scintigraphy for staging and treatment monitoring. PATIENTS AND METHODS: Retrospective chart review was performed of mCRPC patients who received 6 cycles of radium-223 and who underwent bone scintigraphy before start of radium-223 and after 3 and 6 cycles of treatment...
April 23, 2018: Clinical Genitourinary Cancer
Giuseppe Procopio, Michele Prisciandaro, Roberto Iacovelli, Enrico Cortesi, Giuseppe Fornarini, Gaetano Facchini, Giacomo Cartenì, Roberto Sabbatini, Gabriella Del Bene, Luca Galli, Claudia Caserta, Andrea Giovanni Multari, Marco Bregni, Francesco Massari, Sebastiano Buti, Ugo De Giorgi, Fable Zustovich, Michele Milella, Fabio Calabrò, Maria Laura Mancini, Giampaolo Tortora, Claudio Vernieri, Daniele Santini, Mariella Sorarù, Riccardo Ricotta, Cristina Masini, Marcello Tucci, Stefano Luzi Fedeli, Cinzia Ortega, Antonella Mecozzi, Raffaele Ratta, Cora N Sternberg, Elena Verzoni
BACKGROUND: The randomized phase 3 METEOR study confirmed a survival benefit of cabozantinib over everolimus in patients with metastatic renal-cell carcinoma (mRCC) with disease that progressed after treatment with at least one previous antiangiogenic inhibitor. The aim of this analysis was to evaluate the safety and activity of cabozantinib in an unselected population. METHODS: Data were collected across 24 Italian centers. Cabozantinib therapy was initiated at physician request between September and December 2016...
April 19, 2018: Clinical Genitourinary Cancer
Guru Sonpavde, Gregory Russell Pond, Jonathan E Rosenberg, Toni K Choueiri, Joaquim Bellmunt, Ashley Marie Regazzi, Stephanie A Mullane, Andrea Necchi, Daniele Raggi, Jae-Lyun Lee, Soonil Lee, Joe Simpson, Christina Louise Derleth, Shih-Wen Lin, Dean F Bajorin
INTRODUCTION: Optimal end points in phase 2 trials evaluating salvage therapy for metastatic urothelial carcinoma are necessary to identify promising drugs, particularly immunotherapeutics, where response and progression-free survival may be unreliable. We developed a nomogram using data from phase 2 trials of historical agents to estimate the 12-month overall survival (OS) for patients to which observed survival of nonrandomized data sets receiving immunotherapies could be compared. PATIENTS AND METHODS: Survival and data for major prognostic factors were obtained from phase 2 trials: hemoglobin, performance status, liver metastasis, treatment-free interval, and albumin...
April 6, 2018: Clinical Genitourinary Cancer
Sascha Kaufmann, Giorgio I Russo, Wolfgang Thaiss, Mike Notohamiprodjo, Fabian Bamberg, Jens Bedke, Giuseppe Morgia, Konstantin Nikolaou, Arnulf Stenzl, Stephan Kruck
INTRODUCTION: Multiparametric magnetic resonance imaging (mpMRI) is gaining acceptance to guide targeted biopsy (TB) in prostate cancer (PC) diagnosis. We aimed to compare the detection rate of software-assisted fusion TB (SA-TB) versus cognitive fusion TB (COG-TB) for PC and to evaluate potential clinical features in detecting PC and clinically significant PC (csPC) at TB. PATIENTS AND METHODS: This was a retrospective cohort study of patients with rising and/or persistently elevated prostate-specific antigen (PSA) undergoing mpMRI followed by either transperineal SA-TB or transrectal COG-TB...
April 3, 2018: Clinical Genitourinary Cancer
Waqar Haque, Vivek Verma, E Brian Butler, Bin S Teh
BACKGROUND: Because renal cell carcinoma (RCC) has been traditionally considered a "radioresistant" histology, it may be advantageous to treat brain metastases (BMs) with ablative dosing by means of stereotactic radiosurgery (SRS). This is the first known analysis evaluating utilization of SRS for RCC BMs in the United States. METHODS: The National Cancer Data Base was queried (2005-2014) for metastatic RCC and delivery of intracranial radiotherapy. Patients were stratified into groups receiving either SRS or non-SRS treatment...
April 3, 2018: Clinical Genitourinary Cancer
Kyle Flannery, Xiting Cao, Jinghua He, Yichen Zhong, Amishi Y Shah, Ashish M Kamat
BACKGROUND: Systemic chemotherapy has long been the standard of care for advanced bladder cancer, but its cost implications are poorly understood. The objective of this analysis was to estimate survival and health care costs for patients with stage IV bladder cancer who did or did not receive chemotherapy. PATIENTS AND METHODS: This was a retrospective cohort study of patients identified in the Surveillance, Epidemiology, and End Results-Medicare database with a new primary diagnosis of stage IV bladder cancer between January 2007 and December 2011...
March 27, 2018: Clinical Genitourinary Cancer
Jun Yang Chia, Hoi Yin Loi, Lih Kin Khor, King Chien Joe Lee, Yi Heng Seow
No abstract text is available yet for this article.
March 27, 2018: Clinical Genitourinary Cancer
Kimiharu Takamatsu, Ryuichi Mizuno, Minami Omura, Shinya Morita, Kazuhiro Matsumoto, Kazunobu Shinoda, Takeo Kosaka, Toshikazu Takeda, Toshiaki Shinojima, Eiji Kikuchi, Hiroshi Asanuma, Masafumi Oyama, Shuji Mikami, Mototsugu Oya
BACKGROUND: Almost half of patients with metastatic renal-cell carcinoma (mRCC) are classified as intermediate risk by the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model. The aim of this study was to evaluate whether baseline C-reactive protein (CRP) levels predict overall survival (OS) in intermediate-risk group mRCC patients. PATIENTS AND METHODS: Data from 107 intermediate-risk group mRCC patients receiving first-line targeted therapy were retrospectively reviewed...
March 27, 2018: Clinical Genitourinary Cancer
Andrew W Hahn, David M Gill, Roberto H Nussenzveig, Austin Poole, Jim Farnham, Lisa Cannon-Albright, Neeraj Agarwal
BACKGROUND: The HSD3B1 gene encodes the enzyme 3β-hydroxysteroid dehydrogenase-1 (3βHSD1), which catalyzes adrenal androgen precursors into dihydrotestosterone, the most potent androgen. Recently, the HSD3B1 (1245C) variant was shown to predict shorter duration of response to androgen deprivation therapy with medical or surgical castration in the setting of castration-sensitive prostate cancer (CSPC). The HSD3B1 (1245C) variant also predicts longer duration of response to ketoconazole in men with castration-resistant prostate cancer (CRPC)...
March 27, 2018: Clinical Genitourinary Cancer
Valeria Lami, Lorenzo Ruggera, Alex Anh Ly Nguyen, Giuseppe Nicolò Fanelli, Fabio Vianello, Filiberto Zattoni
No abstract text is available yet for this article.
March 27, 2018: Clinical Genitourinary Cancer
Anders Höög, Magnus Kjellman, Per Mattsson, C Christofer Juhlin, Ivan Shabo
No abstract text is available yet for this article.
March 27, 2018: Clinical Genitourinary Cancer
Alessia Mennitto, Elena Verzoni, Giorgia Peverelli, Alessandra Alessi, Giuseppe Procopio
No abstract text is available yet for this article.
March 27, 2018: Clinical Genitourinary Cancer
Malte Rieken, Luis A Kluth, Harun Fajkovic, Umberto Capitanio, Alberto Briganti, Laura-Maria Krabbe, Vitaly Margulis, Mohammad Abufaraj, Andrea Mari, Beat Foerster, Jay D Raman, Mikhail Regelman, Sabine Brookman-May, Daniel D Sjoberg, Pierre I Karakiewicz, Shahrokh F Shariat
INTRODUCTION: A few studies addressed predictive factors of cancer-specific mortality (CSM) in patients with recurrent renal cell carcinoma (RCC) following surgery. Time to recurrence (TTR) is an important predictor of CSM in various types of cancers. The aim of our study was to describe the course of RCC following disease recurrence and to identify prognostic factors that influence CSM with a special focus on TTR. MATERIALS AND METHODS: Retrospective analysis of 331 patients who experienced disease recurrence after radical nephrectomy (n = 307) or partial nephrectomy (n = 24) with curative intent...
March 24, 2018: Clinical Genitourinary Cancer
Hongzhou Cai, Weizhang Xu, Bin Yu, Xiao Li, Liangjun Zhu, Zicheng Xu, Jin Zhou, Yuxiao Zheng, Qing Zou, Yun Zeng, Xinwei Wang, Ting Xu
INTRODUCTION: Metastatic extramammary Paget disease (EMPD) as a rare intraepithelial carcinoma is fatal. However, no standardized chemotherapy has been established. We provided docetaxel combined with cisplatin to EMPD patients. PATIENTS AND METHODS: A total of 8 patients with metastatic EMPD were included in this study between July 2010 and July 2015 (mean age, 64.4 years); they underwent a mean of 9.4 cycles of chemotherapy. All the patients were treated with chemotherapy (docetaxel 60 mg/m2 on day 1; cisplatin 25 mg/m2 on days 1-3) as first-line treatment for > 6 cycle (at least 21 days per cycle)...
March 23, 2018: Clinical Genitourinary Cancer
Heather Jacene, Leonard Gomella, Evan Y Yu, Eric M Rohren
Radium-223 dichloride is an α-emitting radiopharmaceutical that localizes to bone matrix and is approved for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) and symptomatic bone metastases. The cumulative impact of Ra-223 and other therapeutic agents for metastatic CRPC on myelosuppression in bone marrow is unknown. The phase 3 randomized, double-blind, placebo-controlled ALSYMPCA trial of Ra-223 in patients with CRPC and symptomatic bone metastases demonstrated a significant improvement in overall survival...
March 23, 2018: Clinical Genitourinary Cancer
Jinhee Park, Xiaolong Jiao, Sameer Ghate, Thomas Wilson, Qasim I Ahmad, Nicholas J Vogelzang
BACKGROUND: Pazopanib is among the current standards of care for first-line treatment of patients with unresectable advanced renal-cell carcinoma (aRCC) or metastatic renal-cell carcinoma. This real-world study aimed to characterize those with long-term response to pazopanib in the treatment of aRCC in a community oncology setting, and to identify predictors of long-term response. PATIENTS AND METHODS: aRCC patients treated with first-line pazopanib were classified as having long-term or non-long-term response (progression-free survival [PFS] of ≥ 18 or < 18 months, respectively)...
March 23, 2018: Clinical Genitourinary Cancer
F Anthony Greco, John D Hainsworth
BACKGROUND: Improved diagnostic methods, including gene expression profiling, allow identification of the tissue of origin in most patients with carcinoma of unknown primary site (CUP). Patients with an occult renal cell carcinoma (RCC) are of particular interest, because effective treatment for advanced RCC has no overlap with the empiric chemotherapy used traditionally for CUP. We report the clinical characteristics, pathologic features, and response to RCC-specific treatment in CUP patients identified as RCC using a molecular cancer classifier assay (MCCA)...
March 9, 2018: Clinical Genitourinary Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"